Alzamend NeuroALZN
ALZN
About: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Employees: 7
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
85% more capital invested
Capital invested by funds: $71.2K [Q3] → $132K (+$60.6K) [Q4]
42% more funds holding
Funds holding: 12 [Q3] → 17 (+5) [Q4]
1.0% more ownership
Funds ownership: 1.08% [Q3] → 2.09% (+1.0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
2,885%
upside
Avg. target
$20
2,885%
upside
High target
$20
2,885%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 27% 1-year accuracy 19 / 70 met price target | 2,885%upside $20 | Buy Maintained | 17 Mar 2025 |
Financial journalist opinion
Neutral
Zacks Investment Research
1 week ago
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
3 weeks ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with Alzheimer's in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
Neutral
GlobeNewsWire
1 month ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital
Neutral
GlobeNewsWire
1 month ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
Neutral
GlobeNewsWire
1 month ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with BD, which is expected to commence in the third quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
Neutral
GlobeNewsWire
1 month ago
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate the first of five highly anticipated phase II clinical studies of AL001, with the first study, in healthy human subjects, expected to commence in the second quarter of 2025. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
Positive
Zacks Investment Research
2 months ago
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
Here is how Alzamend Neuro, Inc. (ALZN) and Beam Therapeutics Inc. (BEAM) have performed compared to their sector so far this year.
Positive
Benzinga
7 months ago
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.
Neutral
Business Wire
8 months ago
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it is partnering with Massachusetts General Hospital as its contract research organization (“CRO”) to conduct first of its kind Phase II clinical study of AL001.
Neutral
Business Wire
11 months ago
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
ATLANTA--(BUSINESS WIRE)---- $ALZN #10_day_termination_process_started--Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program.
Charts implemented using Lightweight Charts™